Literature DB >> 34549976

Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.

Laura A VanBlargan1,2, Pavle S Milutinovic1, Leslie Goo1, Christina R DeMaso1, Anna P Durbin3, Stephen S Whitehead4, Theodore C Pierson1, Kimberly A Dowd1.   

Abstract

Dengue virus cocirculates globally as four serotypes (DENV1 to -4) that vary up to 40% at the amino acid level. Viral strains within a serotype further cluster into multiple genotypes. Eliciting a protective tetravalent neutralizing antibody response is a major goal of vaccine design, and efforts to characterize epitopes targeted by polyclonal mixtures of antibodies are ongoing. Previously, we identified two E protein residues (126 and 157) that defined the serotype-specific antibody response to DENV1 genotype 4 strain West Pac-74. DENV1 and DENV2 human vaccine sera neutralized DENV1 viruses incorporating these substitutions equivalently. In this study, we explored the contribution of these residues to the neutralization of DENV1 strains representing distinct genotypes. While neutralization of the genotype 1 strain TVP2130 was similarly impacted by mutation at E residues 126 and 157, mutation of these residues in the genotype 2 strain 16007 did not markedly change neutralization sensitivity, indicating the existence of additional DENV1 type-specific antibody targets. The accessibility of antibody epitopes can be strongly influenced by the conformational dynamics of virions and modified allosterically by amino acid variation. We found that changes at E domain II residue 204, shown previously to impact access to a poorly accessible E domain III epitope, impacted sensitivity of DENV1 16007 to neutralization by vaccine immune sera. Our data identify a role for minor sequence variation in changes to the antigenic structure that impacts antibody recognition by polyclonal immune sera. Understanding how the many structures sampled by flaviviruses influence antibody recognition will inform the design and evaluation of DENV immunogens. IMPORTANCE Dengue virus (DENV) is an important human pathogen that cocirculates globally as four serotypes. Because sequential infection by different DENV serotypes is associated with more severe disease, eliciting a protective neutralizing antibody response against all four serotypes is a major goal of vaccine efforts. Here, we report that neutralization of DENV serotype 1 by polyclonal antibody is impacted by minor sequence variation among virus strains. Our data suggest that mechanisms that control neutralization sensitivity extend beyond variation within antibody epitopes but also include the influence of single amino acids on the ensemble of structural states sampled by structurally dynamic virions. A more detailed understanding of the antibody targets of DENV-specific polyclonal sera and factors that govern their access to antibody has important implications for flavivirus antigen design and evaluation.

Entities:  

Keywords:  dengue virus; humoral immunity; neutralizing antibody; polyclonal antibody; structural dynamics; vaccines

Mesh:

Substances:

Year:  2021        PMID: 34549976      PMCID: PMC8577358          DOI: 10.1128/JVI.00956-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus.

Authors:  Sigrid Elshuber; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  J Gen Virol       Date:  2003-01       Impact factor: 3.891

2.  rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

Authors:  Anna P Durbin; Julie H McArthur; Jennifer A Marron; Joseph E Blaney; Bhavin Thumar; Kimberli Wanionek; Brian R Murphy; Stephen S Whitehead
Journal:  Hum Vaccin       Date:  2006-11-05

3.  Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.

Authors:  Matthew R Vogt; Kimberly A Dowd; Michael Engle; Robert B Tesh; Syd Johnson; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

4.  The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Authors:  Martina Beltramello; Katherine L Williams; Cameron P Simmons; Annalisa Macagno; Luca Simonelli; Nguyen Than Ha Quyen; Soila Sukupolvi-Petty; Erika Navarro-Sanchez; Paul R Young; Aravinda M de Silva; Félix A Rey; Luca Varani; Stephen S Whitehead; Michael S Diamond; Eva Harris; Antonio Lanzavecchia; Federica Sallusto
Journal:  Cell Host Microbe       Date:  2010-09-16       Impact factor: 21.023

5.  Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.

Authors:  Scott A Smith; Ruklanthi de Alwis; Nurgun Kose; Anna P Durbin; Stephen S Whitehead; Aravinda M de Silva; James E Crowe
Journal:  J Infect Dis       Date:  2013-03-22       Impact factor: 5.226

6.  Natural strain variation and antibody neutralization of dengue serotype 3 viruses.

Authors:  Wahala M P B Wahala; Eric F Donaldson; Ruklanthi de Alwis; Mary Ann Accavitti-Loper; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

7.  The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.

Authors:  Theodore C Pierson; Qing Xu; Steevenson Nelson; Theodore Oliphant; Grant E Nybakken; Daved H Fremont; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-04-19       Impact factor: 21.023

Review 8.  The structural immunology of antibody protection against West Nile virus.

Authors:  Michael S Diamond; Theodore C Pierson; Daved H Fremont
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

9.  Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope.

Authors:  S Kyle Austin; Kimberly A Dowd; Bimmi Shrestha; Christopher A Nelson; Melissa A Edeling; Syd Johnson; Theodore C Pierson; Michael S Diamond; Daved H Fremont
Journal:  PLoS Pathog       Date:  2012-10-04       Impact factor: 6.823

Review 10.  The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.

Authors:  Félix A Rey; Karin Stiasny; Marie-Christine Vaney; Mariano Dellarole; Franz X Heinz
Journal:  EMBO Rep       Date:  2017-12-27       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.